Schizophrenia- Pipeline Insight, 2025
Description
DelveInsight’s, “Schizophrenia- Pipeline Insight, 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Schizophrenia: Overview
Schizophrenia is a chronic, severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by episodes of psychosis, which involve disturbances in thought processes, perceptions, emotional responsiveness, and social interactions. Schizophrenia affects about 1% of the population worldwide and typically manifests in late adolescence or early adulthood. The exact cause of schizophrenia is not fully understood, but it is believed to result from a complex interplay of genetic, environmental, and neurobiological factors.
The symptoms of schizophrenia are generally categorized into positive, negative, and cognitive symptoms. Positive symptoms include hallucinations (often auditory), delusions (false beliefs), and disorganized thinking and speech. Negative symptoms refer to diminished emotional expression, lack of motivation, and social withdrawal. Cognitive symptoms affect memory, attention, and executive functioning, leading to difficulty in performing daily activities. These symptoms can vary in severity and may fluctuate over time, with periods of exacerbation and remission. The etiology of schizophrenia is multifactorial, involving genetic predisposition, prenatal and perinatal factors, and psychosocial stressors. Genetic studies indicate a high heritability, with several susceptibility genes identified. Environmental factors such as prenatal exposure to infections, malnutrition, and psychosocial stressors during early development may also contribute. The pathophysiology of schizophrenia involves dysregulation of neurotransmitters, particularly dopamine, glutamate, and serotonin, leading to abnormalities in brain structure and function. Neuroimaging studies have shown changes in brain regions such as the prefrontal cortex and hippocampus, as well as alterations in brain connectivity.
Diagnosing schizophrenia is based on clinical assessment, including a thorough psychiatric evaluation and medical history. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria are commonly used, which require the presence of two or more core symptoms (delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms) for a significant portion of time during a one-month period. Other conditions, such as substance use disorders and mood disorders with psychotic features, must be ruled out. Additionally, the duration of symptoms should persist for at least six months. Treatment for schizophrenia involves a combination of pharmacotherapy, psychotherapy, and social support. Antipsychotic medications are the cornerstone of treatment, with second-generation antipsychotics (such as risperidone, olanzapine, and aripiprazole) being commonly prescribed due to their efficacy and lower risk of extrapyramidal side effects compared to first-generation antipsychotics. Psychosocial interventions, including cognitive-behavioral therapy (CBT), family therapy, and social skills training, are crucial in addressing the cognitive and social deficits associated with the disorder. Additionally, community support services, vocational rehabilitation, and educational programs play a vital role in improving the quality of life and functional outcomes for individuals with schizophrenia. Early intervention and a comprehensive, multidisciplinary approach are essential for optimizing treatment outcomes.
""Schizophrenia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Schizophrenia pipeline landscape is provided which includes the disease overview and Schizophrenia treatment guidelines. The assessment part of the report embraces, in depth Schizophrenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Schizophrenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Schizophrenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Schizophrenia Emerging Drugs
Further product details are provided in the report……..
Schizophrenia: Therapeutic Assessment
This segment of the report provides insights about the different Schizophrenia drugs segregated based on following parameters that define the scope of the report, such as:
Schizophrenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Schizophrenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Schizophrenia drugs.
Schizophrenia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Schizophrenia: Overview
Schizophrenia is a chronic, severe mental disorder that affects how a person thinks, feels, and behaves. It is characterized by episodes of psychosis, which involve disturbances in thought processes, perceptions, emotional responsiveness, and social interactions. Schizophrenia affects about 1% of the population worldwide and typically manifests in late adolescence or early adulthood. The exact cause of schizophrenia is not fully understood, but it is believed to result from a complex interplay of genetic, environmental, and neurobiological factors.
The symptoms of schizophrenia are generally categorized into positive, negative, and cognitive symptoms. Positive symptoms include hallucinations (often auditory), delusions (false beliefs), and disorganized thinking and speech. Negative symptoms refer to diminished emotional expression, lack of motivation, and social withdrawal. Cognitive symptoms affect memory, attention, and executive functioning, leading to difficulty in performing daily activities. These symptoms can vary in severity and may fluctuate over time, with periods of exacerbation and remission. The etiology of schizophrenia is multifactorial, involving genetic predisposition, prenatal and perinatal factors, and psychosocial stressors. Genetic studies indicate a high heritability, with several susceptibility genes identified. Environmental factors such as prenatal exposure to infections, malnutrition, and psychosocial stressors during early development may also contribute. The pathophysiology of schizophrenia involves dysregulation of neurotransmitters, particularly dopamine, glutamate, and serotonin, leading to abnormalities in brain structure and function. Neuroimaging studies have shown changes in brain regions such as the prefrontal cortex and hippocampus, as well as alterations in brain connectivity.
Diagnosing schizophrenia is based on clinical assessment, including a thorough psychiatric evaluation and medical history. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria are commonly used, which require the presence of two or more core symptoms (delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms) for a significant portion of time during a one-month period. Other conditions, such as substance use disorders and mood disorders with psychotic features, must be ruled out. Additionally, the duration of symptoms should persist for at least six months. Treatment for schizophrenia involves a combination of pharmacotherapy, psychotherapy, and social support. Antipsychotic medications are the cornerstone of treatment, with second-generation antipsychotics (such as risperidone, olanzapine, and aripiprazole) being commonly prescribed due to their efficacy and lower risk of extrapyramidal side effects compared to first-generation antipsychotics. Psychosocial interventions, including cognitive-behavioral therapy (CBT), family therapy, and social skills training, are crucial in addressing the cognitive and social deficits associated with the disorder. Additionally, community support services, vocational rehabilitation, and educational programs play a vital role in improving the quality of life and functional outcomes for individuals with schizophrenia. Early intervention and a comprehensive, multidisciplinary approach are essential for optimizing treatment outcomes.
""Schizophrenia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Schizophrenia pipeline landscape is provided which includes the disease overview and Schizophrenia treatment guidelines. The assessment part of the report embraces, in depth Schizophrenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Schizophrenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Schizophrenia R&D. The therapies under development are focused on novel approaches to treat/improve Schizophrenia.
This segment of the Schizophrenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Schizophrenia Emerging Drugs
- Ulotaront: Sunovion Pharmaceuticals
- Emraclidine: Abbvie
- CY 6463: Cyclerion Therapeutics
Further product details are provided in the report……..
Schizophrenia: Therapeutic Assessment
This segment of the report provides insights about the different Schizophrenia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Schizophrenia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Schizophrenia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Schizophrenia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Schizophrenia drugs.
Schizophrenia Report Insights
- Schizophrenia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Schizophrenia drugs?
- How many Schizophrenia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Schizophrenia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Schizophrenia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Schizophrenia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sunovion Pharmaceuticals
- Denovo BioPharma
- Cyclerion Therapeutics
- Karuna Therapeutics
- Boehringer Ingelheim
- Merck Sharp & Dohme
- MapLight Therapeutics
- Valentech LLC
- Addex Therapeutics
- Biodexa Pharmaceuticals
- Autifony Therapeutics
- Vanda Pharmaceuticals
- Luye Pharma
- Reviva Pharmaceuticals
- SyneuRx
- Avanir Pharmaceuticals
- Newron Pharmaceuticals
- Celon Pharma
- Delpor
- Zhejiang Jingxin Pharmaceutical
- Sirtsei Pharmaceuticals
- Ulotaront
- Enzastaurin
- CY 6463
- KarXT
- Iclepertin
- MK-8189
- ML-007
- VLT-015
- M4 PAM
- MTD211
- Back up modulators
- VHX 896
- Paliperidone palmitate
- Brilaroxazine
- Sodium benzoate
- Deudextromethorphan
- Evenamide
- CPL 500036
- Risperidone controlled-release
- JX 11502MA
- SP 624
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Schizophrenia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Schizophrenia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Ulotaront: Sunovion Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Emraclidine: Abbvie
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- CY 6463: Cyclerion Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Schizophrenia Key Companies
- Schizophrenia Key Products
- Schizophrenia- Unmet Needs
- Schizophrenia- Market Drivers and Barriers
- Schizophrenia- Future Perspectives and Conclusion
- Schizophrenia Analyst Views
- Schizophrenia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
